Misperception of estrogen activity in patients treated with an estrogen receptor antagonist

被引：9

作者：

Elguero, Sonia ^{[1
]}

Patel, Bansari ^{[1
]}

Liu, James H. ^{[1
]}

机构：

[1] Univ Hosp, Case Med Ctr, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, Cleveland, OH 44106 USA

来源：

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY | 2014年 / 211卷 / 03期

关键词：

estradiol; estrogen activity; immunoassay; postmenopausal; POSTMENOPAUSAL WOMEN; BREAST-CANCER; FULVESTRANT; ESTRADIOL;

D O I：

10.1016/j.ajog.2014.05.038

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Measurement of estradiol is an important marker of ovarian function. At low levels, accurate measurement has been difficult because of unique characteristics of immunoassay kits. We present this case to emphasize the importance of accurate estimation of estrogen activity and estradiol levels to avoid unnecessary surgical intervention.

引用

页码：E1 / E2

页数：2

共 9 条

[1] Fulvestrant for advanced breast cancer: A meta-analysis [J].

Al-Mubarak, Mustafa ;

Sacher, Adrian G. ;

Ocana, Alberto ;

Vera-Badillo, Francisco ;

Seruga, Bostjan ;

Amir, Eitan .

CANCER TREATMENT REVIEWS, 2013, 39 (07) :753-758

[2] FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer [J].

Bergh, Jonas ;

Jonsson, Per-Ebbe ;

Lidbrink, Elisabet Kerstin ;

Trudeau, Maureen ;

Eiermann, Wolfgang ;

Brattstrom, Daniel ;

Lindemann, Justin P. O. ;

Wiklund, Fredrik ;

Henriksson, Roger .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) :1919-1925

[3] Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer [J].

Di Leo, Angelo ;

Jerusalem, Guy ;

Petruzelka, Lubos ;

Torres, Roberto ;

Bondarenko, Igor N. ;

Khasanov, Rustem ;

Verhoeven, Didier ;

Pedrini, Jose L. ;

Smirnova, Iya ;

Lichinitser, Mikhail R. ;

Pendergrass, Kelly ;

Garnett, Sally ;

Lindemann, Justin P. O. ;

Sapunar, Francisco ;

Martin, Miguel .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (30) :4594-4600

[4] Deficits in plasma oestradiol measurement in studies and management of breast cancer [J].

Dowsett, M ;

Folkerd, E .

BREAST CANCER RESEARCH, 2005, 7 (01) :1-4

[5]

Geisler J, 1998, CLIN CANCER RES, V4, P2089

[6] Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action [J].

Osborne, CK ;

Wakeling, A ;

Nicholson, RI .

BRITISH JOURNAL OF CANCER, 2004, 90 (Suppl 1) :S2-S6

[7] Challenges to the Measurement of Estradiol: An Endocrine Society Position Statement [J].

Rosner, William ;

Hankinson, Susan E. ;

Sluss, Patrick M. ;

Vesper, Hubert W. ;

Wierman, Margaret E. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (04) :1376-1387

[8] Measurement of Estradiol-Challenges Ahead [J].

Stanczyk, Frank Z. ;

Clarke, Nigel J. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (01) :56-58

[9] Limitations of Direct Immunoassays for Measuring Circulating Estradiol Levels in Postmenopausal Women and Men in Epidemiologic Studies [J].

Stanczyk, Frank Z. ;

Jurow, Jordan ;

Hsing, Ann W. .

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2010, 19 (04) :903-906

← 1 →